Bausch Christoph Lawrence 4
4 · SAB Biotherapeutics, Inc. · Filed Aug 28, 2025
Insider Transaction Report
Form 4
Bausch Christoph Lawrence
CHIEF OPERATING OFFICER
Transactions
- Award
Stock Option (right to buy)
2025-08-26+600,000→ 600,000 totalExercise: $2.17Exp: 2035-08-26→ Common Stock (600,000 underlying)
Footnotes (3)
- [F1]Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share ("Common Stock"), pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended (the "Plan").
- [F2]The awards are subject to the Company's receipt of stockholder approval to amend the Plan, to increase the number of shares of Common Stock available for issuance thereunder.
- [F3]The shares of Common Stock underlying the option vest over a four-year period, vesting 1/4 on March 1, 2026, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.